| Antiinflammatory therapy with canakinumab for atherosclerotic disease PM Ridker, BM Everett, T Thuren, JG MacFadyen, WH Chang, ... New England journal of medicine 377 (12), 1119-1131, 2017 | 7905 | 2017 |
| Rosuvastatin in older patients with systolic heart failure J Kjekshus, E Apetrei, V Barrios, M Böhm, JGF Cleland, JH Cornel, ... New England Journal of Medicine 357 (22), 2248-2261, 2007 | 2061 | 2007 |
| Lenient versus strict rate control in patients with atrial fibrillation IC Van Gelder, HF Groenveld, HJGM Crijns, YS Tuininga, JGP Tijssen, ... New England Journal of Medicine 362 (15), 1363-1373, 2010 | 1427 | 2010 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1367 | 2018 |
| Apixaban with antiplatelet therapy after acute coronary syndrome JH Alexander, RD Lopes, S James, R Kilaru, Y He, P Mohan, DL Bhatt, ... New England Journal of Medicine 365 (8), 699-708, 2011 | 1320 | 2011 |
| Colchicine in patients with chronic coronary disease SM Nidorf, ATL Fiolet, A Mosterd, JW Eikelboom, A Schut, TSJ Opstal, ... New England journal of medicine 383 (19), 1838-1847, 2020 | 1314 | 2020 |
| Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study ML Simoons, W Rutsch, A Vahanian, J Adgey, A Maseri, C Vassanelli, ... Lancet 349 (9063), 1429-1435, 1997 | 1272 | 1997 |
| Renal function as a predictor of outcome in a broad spectrum of patients with heart failure HL Hillege, D Nitsch, MA Pfeffer, K Swedberg, JJV McMurray, S Yusuf, ... Circulation 113 (5), 671-678, 2006 | 1195 | 2006 |
| Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo … PM Ridker, JG MacFadyen, T Thuren, BM Everett, P Libby, RJ Glynn, ... The Lancet 390 (10105), 1833-1842, 2017 | 1193 | 2017 |
| Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial SJ Nicholls, R Puri, T Anderson, CM Ballantyne, L Cho, JJP Kastelein, ... Jama 316 (22), 2373-2384, 2016 | 1122 | 2016 |
| Prasugrel versus clopidogrel for acute coronary syndromes without revascularization MT Roe, PW Armstrong, KAA Fox, HD White, D Prabhakaran, ... New England journal of medicine 367 (14), 1297-1309, 2012 | 1086 | 2012 |
| Thrombin-receptor antagonist vorapaxar in acute coronary syndromes P Tricoci, Z Huang, C Held, DJ Moliterno, PW Armstrong, F Van de Werf, ... New England Journal of Medicine 366 (1), 20-33, 2012 | 901 | 2012 |
| Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled … PM Ridker, JG MacFadyen, BM Everett, P Libby, T Thuren, RJ Glynn, ... The Lancet 391 (10118), 319-328, 2018 | 815 | 2018 |
| Early invasive versus selectively invasive management for acute coronary syndromes RJ de Winter, F Windhausen, JH Cornel, PHJM Dunselman, CL Janus, ... New England Journal of Medicine 353 (11), 1095-1104, 2005 | 738 | 2005 |
| Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary … JJ Bax, W Wijns, JH Cornel, FC Visser, E Boersma, PM Fioretti Journal of the American College of Cardiology 30 (6), 1451-1460, 1997 | 728 | 1997 |
| Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial S James, DJ Angiolillo, JH Cornel, D Erlinge, S Husted, F Kontny, J Maya, ... European heart journal 31 (24), 3006-3016, 2010 | 547 | 2010 |
| Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial S James, A Budaj, P Aylward, KK Buck, CP Cannon, JH Cornel, ... Circulation 122 (11), 1056-1067, 2010 | 524 | 2010 |
| Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable … JJ Bax, D Poldermans, A Elhendy, JH Cornel, E Boersma, R Rambaldi, ... Journal of the American College of Cardiology 34 (1), 163-169, 1999 | 483 | 1999 |
| Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure BM Everett, JH Cornel, M Lainscak, SD Anker, A Abbate, T Thuren, ... Circulation 139 (10), 1289-1299, 2019 | 480 | 2019 |
| Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial RC Becker, JP Bassand, A Budaj, DM Wojdyla, SK James, JH Cornel, ... European heart journal 32 (23), 2933-2944, 2011 | 471 | 2011 |
